CoChat
Sign Up
PreprintCited by 2

The DOI matches its Crossref record; the references it cites are not checked yet.

HA-Coated PLGA Nanoparticles Loaded with Apigenin for Colon Cancer with High Expression of CD44

Yang, Bo, Mao, Yongqing, Zhang, Yanjun, Hao, Yue, Guo, Meitong, Li, Bian, Peng, Haisheng·2023
DOI 10.20944/preprints202310.0299.v1

Preprint — published as 10.3390/molecules28227565

Open this paper in CoChat — free account

Abstract

Apigenin (API) possesses excellent antitumor properties, but its limited water solubility and low bioavailability restrict its therapeutic impact. Thus, a suitable delivery systems is needed to overcome these limitations and improve the therapeutic efficiency. Poly (lactic-co-glycolic acid) (PLGA) is a copolymer extensively utilized in drug delivery. Hyaluronic acid (HA) is a major extracellular matrix and can specifically bind with CD44 on colon cancer cells. Chitosan (CS) can serve as an intermediate binding with HA and PLGA. Herein, we aimed to perpare receptor-selective HA-coated PLGA nanoparticles (NPs) for colon cancer with high expression of CD44. Firstly, API was encapsulated in PLGA to obtain PLGA-API-NPs, which were then sequentially combined with CS and HA to form HA-coated PLGA NPs. HA coated PLGA NPs had a stronger sustained-release capability. Cellular uptake of HA coated PLGA NPs was enhanced in HT-29 cells with high expression of CD44. HA-PLGA-DiR-NPs can target specificity towards the HT-29 ectopic tumor model. Overall, HA coated PLGA NPs was an effectively drug deliver platform for API in treatment of colon cancer with high expression of CD44.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.20944/preprints202310.0299.v1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

Cited by 2

Research works printed but not linked: 34

  1. Salehi, B.; Venditti, A.; Sharifi-Rad, M.; Kręgiel, D.; Sharifi-Rad, J.; Durazzo, A.; Lucarini, M.; Santini, A.; Souto, E.B.; Novellino, E.; et al. The Therapeutic Potential of Apigenin. Int. J. Mol. Sci. 2019, 20, 1305. [CrossRef] · DOI
  2. Majma Sanaye, P.; Mojaveri, M.R.; Ahmadian, R.; Sabet Jahromi, M.; Bahramsoltani, R. Apigenin and its dermatological applications: A comprehensive review. Phytochemistry 2022, 203, 113390. [CrossRef] · DOI
  3. Imran, M.; Aslam Gondal, T.; Atif, M.; Shahbaz, M.; Batool Qaisarani, T.; Hanif Mughal, M.; Salehi, B.; Martorell, M.; Sharifi-Rad, J. Apigenin as an anticancer agent. Phytother. Res. 2020, 34, 1812-1828. [CrossRef] · DOI
  4. Singh, D.; Gupta, M.; Sarwat, M.; Siddique, H.R. Apigenin in cancer prevention and therapy: A systematic review and meta- analysis of animal models. Crit. Rev. Oncol. Hematol. 2022, 176, 103751. [CrossRef] · DOI
  5. Yoon, J.H.; Kim, M.Y.; Cho, J.Y. Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer. Int. J. Mol. Sci. 2023, 24, 1498. [CrossRef] · DOI
  6. Madunić, J.; Madunić, I.V.; Gajski, G.; Popić, J.; Garaj-Vrhovac, V. Apigenin: A dietary flavonoid with diverse anticancer properties. Cancer Lett. 2018, 413, 11-22. [CrossRef] · DOI
  7. Yang, J.; Pi, C.; Wang, G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed. Pharmacother. 2018, 103, 699-707. [CrossRef] · DOI
  8. Tang, D.; Chen, K.; Huang, L.; Li, J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert. Opin. Drug Metab. Toxicol. 2017, 13, 323-330. [CrossRef] [PubMed] · DOI
  9. Su, Y.; Zhang, B.; Sun, R.; Liu, W.; Zhu, Q.; Zhang, X.; Wang, R.; Chen, C. PLGA-based biodegradable microspheres in drug delivery: Recent advances in research and application. Drug Deliv. 2021, 28, 1397-1418. [CrossRef] [PubMed] · DOI
  10. Ding, D.; Zhu, Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater. Sci. Eng. C Mater. Biol. Appl. 2018, 92, 1041-1060. [CrossRef] [PubMed] · DOI
  11. Rocha, C.V.; Gonçalves, V.; da Silva, M.C.; Bañobre-López, M.; Gallo, J. PLGA-Based Composites for Various Biomedical Applications. Int. J. Mol. Sci. 2022, 23, 2034. [CrossRef] · DOI
  12. Chereddy, K.K.; Payen, V.L.; Préat, V. PLGA: From a classic drug carrier to a novel therapeutic activity contributor. J. Control Release 2018, 289, 10-13. [CrossRef] · DOI
  13. Shariati, A.; Chegini, Z.; Ghaznavi-Rad, E.; Zare, E.N.; Hosseini, S.M. PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm. Front. Cell Infect. Microbiol. 2022, 12, 926363. [CrossRef] [PubMed] · DOI
  14. Hoarau, A.; Polette, M.; Coraux, C. Lung Hyaluronasome: Involvement of Low Molecular Weight Ha (Lmw-Ha) in Innate Immunity. Biomolecules 2022, 12, 658. [CrossRef] [PubMed] · DOI
  15. Mattheolabakis, G.; Milane, L.; Singh, A.; Amiji, M.M. Hyaluronic acid targeting of CD44 for cancer therapy: From receptor biology to nanomedicine. J. Drug Target. 2015, 23, 605-618. [CrossRef] · DOI · Paper page
  16. Cannito, S.; Bincoletto, V.; Turato, C.; Pontisso, P.; Scupoli, M.T.; Ailuno, G.; Andreana, I.; Stella, B.; Arpicco, S.; Bocca, C. Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. Molecules 2022, 27, 1062. [CrossRef] [PubMed] · DOI
  17. Siddiqui, L.; Hasan, N.; Mishra, P.K.; Gupta, N.; Singh, A.T.; Madaan, A.; Jaggi, M.; Saad, S.; Ekielski, A.; Iqbal, Z.; et al. CD44 mediated colon cancer targeting mutlifaceted lignin nanoparticles: Synthesis, in vitro characterization and in vivo efficacy studies. Int. J. Pharm. 2023, 643, 123270. [CrossRef] [PubMed] · DOI
  18. Babu, A.; Amreddy, N.; Muralidharan, R.; Pathuri, G.; Gali, H.; Chen, A.; Zhao, Y.D.; Munshi, A.; Ramesh, R. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Sci. Rep. 2017, 7, 14674. [CrossRef] · DOI
  19. Zhu, C.; Zhang, H.; Li, W.; Luo, L.; Guo, X.; Wang, Z.; Kong, F.; Li, Q.; Yang, J.; Du, Y.; et al. Suppress orthotopic colon cancer and its metastasis through exact targeting and highly selective drug release by a smart nanomicelle. Biomaterials 2018, 161, 144-153. [CrossRef] · DOI · Paper page
  20. Karabiyik Acar, O.; Kayitmazer, A.B.; Torun Kose, G. Hyaluronic Acid/Chitosan Coacervate-Based Scaffolds. Biomacromolecules 2018, 19, 1198-1211. [CrossRef] · DOI
  21. Jian, Y.S.; Chen, C.W.; Lin, C.A.; Yu, H.P.; Lin, H.Y.; Liao, M.Y.; Wu, S.H.; Lin, Y.F.; Lai, P.S. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo. Int. J. Nanomed. 2017, 12, 2315-2333. [CrossRef] · DOI
  22. Cutler, M.J.; Lowthers, E.L.; Richard, C.L.; Hajducek, D.M.; Spagnuolo, P.A.; Blay, J. Chemotherapeutic agents attenuate CXCL12- mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26. BMC Cancer 2015, 15, 882. [CrossRef] [PubMed] · DOI
  23. Lin, C.W.; Lu, K.Y.; Wang, S.Y.; Sung, H.W.; Mi, F.L. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release. Acta Biomater. 2016, 35, 280-292. [CrossRef] [PubMed] · DOI
  24. Kumar, S.; Lather, V.; Pandita, D. A facile green approach to prepare core-shell hybrid PLGA nanoparticles for resveratrol delivery. Int. J. Biol. Macromol. 2016, 84, 380-384. [CrossRef] [PubMed] · DOI
  25. Wang, M.; Firrman, J.; Liu, L.; Yam, K. A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota. Biomed. Res. Int. 2019, 2019, 7010467. [CrossRef] · DOI
  26. Hashemi, M.; Shamshiri, A.; Saeedi, M.; Tayebi, L.; Yazdian-Robati, R. Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs. Arch. Biochem. Biophys. 2020, 691, 108485. [CrossRef] · DOI
  27. Graf, N.; Bielenberg, D.R.; Kolishetti, N.; Muus, C.; Banyard, J.; Farokhzad, O.C.; Lippard, S.J. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano 2012, 6, 4530-4539. [CrossRef] · DOI
  28. Nethi, S.K.; Bhatnagar, S.; Prabha, S. Synthetic Receptor-Based Targeting Strategies to Improve Tumor Drug Delivery. AAPS PharmSciTech 2021, 22, 93. [CrossRef] · DOI
  29. Farokhzad, O.C.; Karp, J.M.; Langer, R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert. Opin. Drug Deliv. 2006, 3, 311-324. [CrossRef] · DOI
  30. Kumar Shukla, M.; Parihar, A.; Karthikeyan, C.; Kumar, D.; Khan, R. Multifunctional GQDs for receptor targeting, drug delivery, and bioimaging in pancreatic cancer. Nanoscale 2023, 15, 14698-14716. [CrossRef] · DOI
  31. Bayer, I.S. Hyaluronic Acid and Controlled Release: A Review. Molecules 2020, 25, 2649. [CrossRef] [PubMed] · DOI
  32. Singh, S.; Singha, P. Effect of Modifications in Poly (Lactide-co-Glycolide) (PLGA) on Drug Release and Degradation Characteris- tics: A Mini Review. Curr. Drug Deliv. 2021, 18, 1378-1390. [CrossRef] [PubMed] · DOI
  33. Ramezani, M.; Ebrahimian, M.; Hashemi, M. Current Strategies in the Modification of PLGA-based Gene Delivery System. Curr. Med. Chem. 2017, 24, 728-739. [CrossRef] [PubMed] · DOI
  34. Park, J.K.; Utsumi, T.; Seo, Y.E.; Deng, Y.; Satoh, A.; Saltzman, W.M.; Iwakiri, Y. Cellular distribution of injected PLGA- nanoparticles in the liver. Nanomedicine 2016, 12, 1365-1374. [CrossRef · DOI

Metadata

Authors
Yang, B., Mao, Y., Zhang, Y., Hao, Y., Guo, M., Li, B., & Peng, H.
Publisher
MDPI AG
Published
2023-10-05
DOI
10.20944/preprints202310.0299.v1
Cited by
2
Type
Preprint
Licence
creativecommons.org/licenses/by/4.0 (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review